Loncastuximab tesirine FDA Approval Status
FDA Approved: No
Generic name: loncastuximab tesirine
Company: ADC Therapeutics SA
Treatment for: Diffuse Large B-cell Lymphoma
Loncastuximab tesirine (Lonca, formerly ADCT-402) is an antibody drug conjugate (composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin) in development for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Development Timeline for loncastuximab tesirine
|Sep 24, 2020||ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.